In a study conducted by K.hermansen et al., the basal insulin Detemir along with short-acting insulin, and basal insulin NPH along with short-acting regular insulin in type 1 diabetic patients within 18 weeks were compared and found that there was less weight gain and hypoglycemia risk in patients receiving insulin Detemir along with insulin aspart compared with those who received NPH and regular insulin (21). The gene discussed is INS; the disease is type 1 diabetes mellitus.